<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is defined as an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> characterized by <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> or obstetrical morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>These features are linked to the presence in blood of autoantibodies against negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> or <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding proteins </plain></SENT>
<SENT sid="2" pm="."><plain>Obstetric morbidity includes <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortion</z:e> (early and late) and severe pre-<z:hpo ids='HP_0100601'>eclampsia</z:hpo> (P-EC)/<z:mp ids='MP_0010163'>hemolysis</z:mp>, <z:hpo ids='HP_0002910'>elevated liver enzymes</z:hpo>, low platelets (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HELLP</z:e>) syndrome, and/or severe <z:mp ids='MP_0006372'>placental insufficiency</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Criteria that define the major clinical and laboratory events were published in revised forms in the Sydney recommendations in 2006 </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed the blood of patients with severe P-EC according to the subgroups based on the 2006 revised criteria definition and compared these results with women after uncomplicated pregnancy and delivery </plain></SENT>
<SENT sid="5" pm="."><plain>We found 20% elevated <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:chebi fb="21" ids="53713">APAs</z:chebi>) in women with severe P-EC (group I, 7.5%; group IIa, 5.0%; group IIb, 5.0%; group IIc, 2.5%) </plain></SENT>
<SENT sid="6" pm="."><plain>The increased <z:chebi fb="21" ids="53713">APAs</z:chebi> were observed only in women with severe P-EC (odds ratio: 2.45; 95% confidence interval, 1.01 to 4.3) and not in patients with severe P-EC at &gt;34 weeks of gestation </plain></SENT>
<SENT sid="7" pm="."><plain>According to our retrospective observation, we recommend the determination of anticardiolipin antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, and Î²-2 glycoprotein-1 antibodies in patients with severe P-EC at &lt;34 weeks of gestation </plain></SENT>
</text></document>